Discover and read the best of Twitter Threads about #cardioonc

Most recents (9)

#JACCCardioOnc #Tweetorial: Along the spectrum of cancer Tx, #YeSCCT has a lot to offer regarding identifying subclinical #ASCVD, excluding obstructive #cvCAD in cardiotoxicity when appropriate. #CardioOnc, as a field, can gain from incorporating CCT in practice.

🧵1/
#YeSCCT may identify subclinical #ASCVD in cancer patients & survivors. Reviewing previous non-gated thoracic CT scans for CAC may help identify subclinical #cvCAD and start prompt preventive Tx.

#JACCCardioOnc #CardioOnc #MedTwitter #CardioTwitter

2/
Several clinical scenarios in the context of cardiotoxicity may require ruling out obstructive #cvCAD. Cancer pts tend to have ⬆️ risk of complications from invasive procedures➡️ thrombocytopenia & hypercoagulable states. #YeSCCT may derive significant benefit. #JACCCardioOnc

3/ This table shows some possible clinical indications of #YeSC
Read 5 tweets
The new epidemic: ATTR Cardiac #Amyloidosis: Current and Emerging Treatment Strategies

Follow/share this #JACCCardioOnc #Tweetorial!

🧵 1/
ATTR cardiac #amyloidosis: Tip of the iceberg - current and emerging therapies to manage and prevent #heartfailure.

#JACCCardioOnc #CardioOnc

2/
ATTR #amyloidosis: Clinical progression and management strategies 👇

#JACCCardioOnc #CardioOnc

3/
Read 5 tweets
1/ Hot-off-the-press 🔥✍🏽🗣

Precision #CardioOncology: Systems-based Perspective on Tyrosine Kinase Inhibitors & Immune Checkpoint Inhibitors

#PrecisionCardioOnc @SpringerNature

Latest manuscript w/ @MayoClinicCV @mayocvonc & edited by @AnaBaracCardio

rdcu.be/b3q0Y
2/ 🔥✍🏽🗣

A broad spectrum of #CVD toxicities can be seen with targeted therapies or #ICIs

Toxicities of one or the other can include cardiomyopathy, HF, myocarditis, venous or arterial thrombosis, progression of atherosclerosis, QTc prolongation, or arrhythmias

#CardioOnc
3/ 🔥✍🏽🗣

An eminent need is optimal risk management, surveillance, detection, and prevention

The heterogeneities of patient populations, risks, and disease spectra have complicated clinical and translation efforts

#cvPrev #PrevCardioOnc #CardioOnc
Read 13 tweets
AMAZING blog on the important role ED providers play in recognizing the nuances that go into the managing AF in patients on ibrutinib! 👏🏻 Awesome job @iEMPharmD

One of my FAVORITE #cardioonc topics!
Summary of the 🔑 considerations 👇🏻
Clinical conundrum: ibrutinib interferes with each pillar of AF management
Risk scoring tools (CHADS2VASC OR HASBLED) NOT validated in cancer patients‼️
Ibrutinib: Inhibitor 🆇 of PGP & substrate of CYP3A4➡️DDI💊
Ibrutinib ⤴️bleeding risk ALONE & only further in pts on AC ImageImageImageImage
Overall, difficult clinical conundrum, how do we maintain the therapeutic benefit of ibrutinib while ⤵️toxicities⚠️?
As Craig mentioned,🆕BTK inhibitors may ⬇️ risk, BUT data w/acalabrutinib still shows signals of AF risk&bleeding is on-target BTK effect so risk remains Image
Read 4 tweets
1/ Hot-off-the-press!

Tweetorial on Role of Angiotensin‐Converting Enzyme Inhibitors & β‐Blockers in Primary Prevention of Cardiac Dysfunction in Breast Cancer Pts

ahajournals.org/doi/10.1161/JA…

#CardioOnc #CardioOncology #PrevCardioOnc

@avolgman @AnaBaracCardio @DrTochiCardiOnc
2/ Approx 4 million American 👩🏽👩‍🦳 are currently living with a hx of invasive breast ca, w/ 270,000 diagnosed within the past year. Among these 👩🏽👩‍🦳, 64% are aged ≥65 years. Among older 👩🏽👩‍🦳 survivors of breast cancer, cardiovascular disease (#CVD) is the leading cause of death
3/ Are ACEIs and β‐blockers indicated and efficacious for everyone with breast cancer? Should we offer these medications prophylactically to all patients planned for chemotherapy, radiation, or targeted therapy? #CardioOnc #CardioOncology
Read 12 tweets
@onco_cardiology @JStojanovskaMD @MichaelCoMD @DmitryAbramovMD @chiarabd @HeartDocSubha @larsgrowo @SarjuGanatraMD @AnaBaracCardio @AkhilNarangMD @krychtiukmd @vass_vassiliou @DrToniyaSingh @AChoiHeart @AnkurKalraMD @adityadoc1 Incidence of Cardiac Metastases: 1.23%
Primary Cardiac Tumors 0.056%

Can be benign, malignant or pseudotumor
Primary Cardiac tumor- mostly benign

#Cardiac Mass eval: detailed clinical presentation, History, Physical Exam, #echofirst to see the tumor characteristics
Read 13 tweets
1/ Preventive Cardio-Oncology Tutorial #PrevCardioOnc @PrevCardioOnc #CardioOnc #CardioOncology

“The time has come for cardiovascular disease (CVD) prevention to play a more prominent role in cardio-oncology.”

tinyurl.com/PrevCardioOncT…
2/ “A myriad of novel cardiotoxic chemotherapeutic & immunotherapeutic drugs are continuously being developed in #Oncology, with diverse cardiovascular (CV) effects.”

tinyurl.com/PrevCardioOncT…

#PrevCardioOnc @PrevCardioOnc #CardioOnc #CardioOncology
3/ Chest radiation “can result in accelerated atherosclerosis, pericardial disease, valve disease, conduction abnormalities, & cardiomyopathies.”

tinyurl.com/PrevCardioOncT…

#PrevCardioOnc @PrevCardioOnc #CardioOnc #CardioOncology
Read 12 tweets
Here goes it! 🎙

Okay for all those non-oncology experts walking into this situation, let’s take a few steps back 🦶 and give a background on ibrutinib 👩‍🏫📜
Ibrutinib (Ibruvica®️) is a first in class ORAL 💊 Bruton tyrosine kinase (BTK) inhibitor,

Used for the treatment of a variety of B-cell lymphomas and Waldenstrom macroglobulinemia 🧬
Ibrutinub was a paradigm shift in the management of patients with CLL as initial or relapsed refractory cases

✅improved progression-free survival, ✅overall response rates, and ✅ overall survival

This was compared w/ ofatumumab (AKA rituximabs cousin) & ⚠️ chlorambucil ⚠️
Read 17 tweets
Hi guys! I’m kind of in the mood to give a talk this night. So why not talk about #CardioOnc & #whyCMR? #CardioTwitter #JACCCardioOnc
We started our small “shop” in mid 2013, with the help of @DipanJShah, he allowed me to start a small CMR practice at @HMethodistCV. I did that until we got #CardsRads right, then @XRayDUG supported me and I was able to practice CMR at MD Anderson, then our volumes have been ⬆️
In 2017, when we got +300, I got so happy, that we wrote about our CMR experience in a major cancer center. Jon Weinsaft had a great practice at MSK already, so we couldn’t claim it was the first CMR practice in a major cancer center, still we were very happy about it.
Read 10 tweets

Related hashtags

Did Thread Reader help you today?

Support us! We are indie developers!


This site is made by just two indie developers on a laptop doing marketing, support and development! Read more about the story.

Become a Premium Member ($3.00/month or $30.00/year) and get exclusive features!

Become Premium

Too expensive? Make a small donation by buying us coffee ($5) or help with server cost ($10)

Donate via Paypal Become our Patreon

Thank you for your support!